Literature DB >> 22585993

Circumventing cancer drug resistance in the era of personalized medicine.

Levi A Garraway1, Pasi A Jänne.   

Abstract

UNLABELLED: All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). SIGNIFICANCE: Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585993     DOI: 10.1158/2159-8290.CD-12-0012

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  207 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

2.  A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens.

Authors:  Albert Gough; Tong Ying Shun; D Lansing Taylor; Mark Schurdak
Journal:  Methods       Date:  2015-11-04       Impact factor: 3.608

3.  Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Authors:  Jin Kyung Rho; In Yong Lee; Yun Jung Choi; Chang-Min Choi; Jae-Young Hur; Jong Sung Koh; Jaekyoo Lee; Byung-Chul Suh; Ho-Juhn Song; Paresh Salgaonkar; Jungmi Lee; Jaesang Lee; Dong Sik Jung; Sang-Yeob Kim; Dong-Cheol Woo; In-Jeoung Baek; Joo-Yong Lee; Chang Hoon Ha; Young Hoon Sung; Jeong Kon Kim; Woo Sung Kim; Joon Seon Song; Cheol Hyeon Kim; Trever G Bivona; Jae Cheol Lee
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

Review 4.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

5.  Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

Authors:  Joan Montero; Kristopher A Sarosiek; Joseph D DeAngelo; Ophélia Maertens; Jeremy Ryan; Dalia Ercan; Huiying Piao; Neil S Horowitz; Ross S Berkowitz; Ursula Matulonis; Pasi A Jänne; Philip C Amrein; Karen Cichowski; Ronny Drapkin; Anthony Letai
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

6.  Personalized genomic analyses for cancer mutation discovery and interpretation.

Authors:  Siân Jones; Valsamo Anagnostou; Karli Lytle; Sonya Parpart-Li; Monica Nesselbush; David R Riley; Manish Shukla; Bryan Chesnick; Maura Kadan; Eniko Papp; Kevin G Galens; Derek Murphy; Theresa Zhang; Lisa Kann; Mark Sausen; Samuel V Angiuoli; Luis A Diaz; Victor E Velculescu
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

7.  Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways.

Authors:  Seong M Kim; Saurabh G Roy; Bin Chen; Tiffany M Nguyen; Ryan J McMonigle; Alison N McCracken; Yanling Zhang; Satoshi Kofuji; Jue Hou; Elizabeth Selwan; Brendan T Finicle; Tricia T Nguyen; Archna Ravi; Manuel U Ramirez; Tim Wiher; Garret G Guenther; Mari Kono; Atsuo T Sasaki; Lois S Weisman; Eric O Potma; Bruce J Tromberg; Robert A Edwards; Stephen Hanessian; Aimee L Edinger
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

8.  Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Authors:  Monika A Davare; Anna Saborowski; Christopher A Eide; Cristina Tognon; Rebecca L Smith; Johannes Elferich; Anupriya Agarwal; Jeffrey W Tyner; Ujwal P Shinde; Scott W Lowe; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

9.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.